Cargando…

Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis

BACKGROUND: Immune tolerance induction (ITI) aims to eradicate anti-factor VIII (FVIII) antibodies (inhibitors) in persons with hemophilia A. However, this burdensome treatment fails in 10% to 40%. To estimate the chance of ITI success in clinical decision making, it is important to identify the pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oomen, Ilja, Camelo, Ricardo M., Rezende, Suely Meireles, Voorberg, Jan, Mancuso, Maria Elisa, Oldenburg, Johannes, Carcao, Manuel, Matino, Davide, Lillicrap, David, Fischer, Kathelijn, Fijnvandraat, Karin, Gouw, Samantha C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986104/ https://www.ncbi.nlm.nih.gov/pubmed/36891524 http://dx.doi.org/10.1016/j.rpth.2022.100020

Ejemplares similares

Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A
por: Schep, Sarah J., et al.
Publicado: (2021)

Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: The Brazilian Immune Tolerance (BrazIT) Study protocol
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2021)

Hemophilia management: Huge impact of a tiny difference
por: Kloosterman, Fabienne, et al.
Publicado: (2020)

Desmopressin in moderate hemophilia A patients: a treatment worth considering
por: Loomans, Janneke I., et al.
Publicado: (2018)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Development of inhibitors in hemophilia A: An illustrated review
por: Jardim, Letícia Lemos, et al.
Publicado: (2020)

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A— A Systematic Review and Meta-Analysis
por: Abdi, A., et al.
Publicado: (2020)

Molecular Mechanisms of Inhibitor Development in Hemophilia
por: Tieu, Paul, et al.
Publicado: (2020)

Hemophilia A and B: molecular and clinical similarities and differences
por: Castaman, Giancarlo, et al.
Publicado: (2019)

Psychometrics of the patient-reported outcomes measurement information system measures in hemophilia: the applicability of the pediatric item banks
por: Teela, Lorynn, et al.
Publicado: (2023)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
por: Carcao, Manuel, et al.
Publicado: (2019)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study
por: Abdi, Amal, et al.
Publicado: (2021)

Future prospects for the treatment of hemophilia: A global perspective
por: Lillicrap, David
Publicado: (2018)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
por: Isfordink, Cas J., et al.
Publicado: (2021)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
por: Matino, Davide, et al.
Publicado: (2022)

Immune tolerance induction in patients with severe hemophilia A with inhibitors
por: Ryu, Ji Eun, et al.
Publicado: (2015)

Hemophilia Gene Therapy: Approaching the First Licensed Product
por: Batty, Paul, et al.
Publicado: (2021)

Patients’ and health care providers’ perspectives on quality of hemophilia care in the Netherlands: a questionnaire and interview study
por: Brands, Martijn R., et al.
Publicado: (2023)

Twelve months of emicizumab prophylaxis in a severe hemophilia A man with inhibitor who failed immune tolerance induction: effectiveness, economic, and safety outcomes
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce
por: Herzog, Roland W., et al.
Publicado: (2017)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Desmopressin in nonsevere hemophilia A: patient perspectives on use and efficacy
por: Romano, Lorenzo G.R., et al.
Publicado: (2023)

Generic PROMIS item banks in adults with hemophilia for patient‐reported outcome assessment: Feasibility, measurement properties, and relevance
por: Kuijlaars, Isolde A. R., et al.
Publicado: (2021)

Desmopressin for bleeding in non‐severe hemophilia A: Suboptimal use in a real‐world setting
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
por: Dover, Saunya, et al.
Publicado: (2021)

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms
por: Georgescu, Maria T., et al.
Publicado: (2018)

The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review
por: Punt, Marieke C., et al.
Publicado: (2020)

Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines
por: Andersson, Nadine G., et al.
Publicado: (2020)

Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
por: van Balen, Erna C., et al.
Publicado: (2021)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research
por: Dover, Saunya, et al.
Publicado: (2020)

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
por: Blanchette, Victor S., et al.
Publicado: (2021)

Insights into the Molecular Genetic of Hemophilia A and Hemophilia B: The Relevance of Genetic Testing in Routine Clinical Practice
por: Pezeshkpoor, Behnaz, et al.
Publicado: (2022)

Escores de Risco Cardiovascular entre Adultos Assintomáticos com Hemofilia
por: Camelo, Ricardo Mesquita, et al.
Publicado: (2023)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Patient-Centered Digital Health Records and Their Effects on Health Outcomes: Systematic Review
por: Brands, Martijn R, et al.
Publicado: (2022)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lp52v3qtr05jup775lch0g2i1a